Recently, the domestic new crown oral drug Azivudine Tablets has been officially launched online in some pharmacies in Beijing. The current price is 350 yuan per bottle, 35 tablets per bottle.
The reporter noticed that the Azivudine tablets produced by Henan Zhenzhen Biotechnology Co., Ltd. have been officially sold online in the Neptunus chain pharmacy in this city. Patients can place an order through the WeChat mini-program "Neptune Drug Express", fill in the prescription information, and make an appointment place an order.
The current price per bottle is 350 yuan, 35 tablets per bottle, and the specification is 1 mg.
According to the instructions of Azivudine Tablets, the drug specification is divided into two specifications: 1 mg and 3 mg, and only the 1 mg specification is used to treat adult patients with common type of novel coronavirus pneumonia (COVID-19).
The drug is conditionally approved for marketing, and the virus is still mutating. The drug should be studied according to the mutation of the epidemic strain of the new coronavirus to confirm its effectiveness against the current epidemic strain.
Its usage and dosage are to be taken on an empty stomach. In order to ensure the dosage, the tablet should be swallowed whole and not crushed.
The recommended dose for novel coronavirus pneumonia (COVID-19) is 5 mg each time for adult patients, once a day.
When treating novel coronavirus pneumonia, the course of treatment should not exceed 14 days at most.
The National Health and Medical Commission and the State Administration of Traditional Chinese Medicine jointly issued the "Notice on Including Azivudine Tablets in the Diagnosis and Treatment Program for New Coronavirus Pneumonia" on August 9, and included the drug in the "Diagnosis and Treatment Program for New Coronavirus Pneumonia (Ninth Version)", for the treatment of adult patients with common type of novel coronavirus pneumonia (COVID-19).
On November 11, the Joint Defense and Control Mechanism of the State Council issued the "Notice on Further Optimizing the Prevention and Control Measures of New Coronary Pneumonia Epidemic Prevention and Control in a Scientific and Accurate Way", which also clearly pointed out that it is necessary to speed up the storage of drugs related to the treatment of new coronary pneumonia and make a good supply reserve. Meet the drug needs of patients, especially the treatment needs of severe high-risk and elderly patients.
On September 17, the National Medical Insurance Bureau officially announced the "2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog Adjustment List of Drugs that Passed the Formal Review". A total of 343 drugs officially passed the formal review, including Azvudine piece.
The National Medical Insurance Administration stated that under the background of the normalization of the prevention and control of the new crown epidemic, since the first implementation of the self-declaration system for enterprises in the medical insurance drug catalog in 2020, the National Medical Insurance Administration has attached great importance to the treatment of new coronary pneumonia, and will be "included in the "New Type". Drugs in the "Diagnosis and Treatment Plan for Coronavirus Pneumonia" are one of the declaration conditions, and a batch of new crown treatment drugs have been included in the medical insurance drug list.
During this application process, follow-up work will be carried out in accordance with the procedures for the new coronary pneumonia treatment drugs that have been declared and passed the formal review, and strive to be officially included in the medical insurance catalog at a reasonable price.